Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.

European journal of clinical pharmacology - 1 Sept 2015

Tomaz Paulo Roberto Xavier, Santos Juliana Rocha, Issa Jaqueline Scholz, Abe Tânia Ogawa, Gaya Patrícia Viviane, Krieger José Eduardo, Pereira Alexandre Costa, Santos Paulo Caleb Júnior Lima

Abstract excerpt

BACKGROUND: Previous studies suggested that polymorphisms in the CYP2B6 gene (which encodes an isoenzyme that metabolizes bupropion) and in the ANKK1 gene (which is located in the ANKK1/DRD2 gene cluster) might influence response to therapy. Thus, the aim of the present study was to evaluate whether the CYP2B6 and ANKK1 polymorphisms are associated with the response to smoking cessation therapies in patients from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bupropion
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Counseling

Share to Cytochrome P-450 CYP2B6

Share to Protein Serine-Threonine Kinases

Share to Smoking Cessation

Share to Tobacco Use Disorder

Share to Treatment Outcome

Source

Identifiers

PMID: 26153084
DOI: 10.1007/s00228-015-1896-x

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.PMID 26153084Read ↗

Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking CessationSemantic proximity Read ↗

Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women.Semantic proximity Read ↗

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.Semantic proximity Read ↗

Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers.Semantic proximity Read ↗

Pharmacogenetic investigation of smoking cessation treatment.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.Semantic proximity Read ↗

CYP2B6 gene single-nucleotide polymorphisms in an Italian population sample and relationship with nicotine dependence.Semantic proximity Read ↗

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.Semantic proximity Read ↗

Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.Semantic proximity Read ↗

Pharmacogenetics and nicotine addiction treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.